Subgroup analysis shows event-free and overall survival improvements in patients with neuroblastoma, suggesting treatment impacts varying eligibility criteria.
Supplementary Figure S2. Event-free survival and overall survival by subgroup analysis according to eligibility criteria (relapsed – high-risk at diagnosis, relapsed – non-high-risk at diagnosis, front-line PRD, front-line with MTD) (A and B) and by age ≤5 years and >5 years (C and D). EFS, event-free survival; HDT, high-dose chemotherapy; HR, high-risk; HRNBL, high-risk neuroblastoma; MTD, major treatment deviations; NBL, neuroblastoma, OS, overall survival; PRD, primary refractory disease; SCR, stem cell rescue; SE, standard error.
No takes yet. Share an insight, caveat, or question.
Lode et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: